文献速递乳腺乳腺X线

基于人群筛查项目中乳腺X线摄影假阳性结果后的间期乳腺癌发生率及组织病理学肿瘤特征

Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program.
PubMed 文献 · Radiology · 2017-12-14

该回顾性研究基于挪威乳腺癌筛查项目2004-2012年789 481次全视野数字乳腺X线摄影筛查(423 445名49-71岁女性),比较筛查阴性后与假阳性后检出的间期乳腺癌的发生率和肿瘤特征。以筛查阴性为参照,假阳性筛查使间期乳腺癌风险增加约三倍(调整OR 3.3,95%CI 2.6-4.2;无穿刺活检者OR 3.3,有穿刺活检者OR 2.8)。筛查阴性后的间期乳腺癌肿瘤特征较假阳性后更不利(肿瘤≤10mm比例更低、淋巴结阳性比例更高)。

要点

  • 假阳性筛查后间期乳腺癌风险约为筛查阴性者的3.3倍(调整OR 3.3,95%CI 2.6-4.2)。
  • 有穿刺活检的假阳性者间期乳腺癌调整OR为2.8(95%CI 1.8-4.4)。
  • 筛查阴性后间期乳腺癌中肿瘤≤10mm比例低于假阳性后(14.3% vs 50.0%,P<.01)。

核心结论

  • 以筛查阴性为参照,假阳性筛查使间期乳腺癌风险增加约三倍;筛查阴性后检出的间期乳腺癌肿瘤特征较既往假阳性筛查后检出者更不利。

研究设计与样本

  • 回顾性研究,经癌症登记法规批准,纳入2004-2012年挪威乳腺癌筛查项目中423 445名49-71岁女性的789 481次全视野数字乳腺X线摄影筛查,数据来自挪威癌症登记处。

诊断标准与关键数值

  • 共诊断1302例间期乳腺癌,其中7.0%(91/1302)在最近一次乳腺影像检查为假阳性筛查的女性中检出;以筛查阴性为参照,无穿刺活检的假阳性者间期乳腺癌调整OR为3.3(95%CI 2.6-4.2),有穿刺活检的假阳性者调整OR为2.8(95%CI 1.8-4.4)。

临床应用与阅片要点

  • 对既往筛查假阳性(尤其伴穿刺活检)的女性,阅片和报告时应意识到其后续间期乳腺癌风险升高;回顾性复核筛查乳腺X线摄影发现42.9%(39/91)的假阳性病例病灶与间期乳腺癌为同一病灶。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To compare rates and tumor characteristics of interval breast cancers (IBCs) detected after a negative versus false-positive screening among women participating in the Norwegian Breast Cancer Screening Program. Materials and Methods The Cancer Registry Regulation approved this retrospective study. Information about 423 445 women aged 49-71 years who underwent 789 481 full-field digital mammographic screening examinations during 2004-2012 was extracted from the Cancer Registry of Norway. Rates and odds ratios of IBC among women with a negative (the reference group) versus a false-positive screening were estimated by using logistic regression models adjusted for age at diagnosis and county of residence. Results A total of 1302 IBCs were diagnosed after 789 481 screening examinations, of which 7.0% (91 of 1302) were detected among women with a false-positive screening as the most recent breast imaging examination before detection. By using negative screening as the reference, adjusted odds ratios of IBCs were 3.3 (95% confidence interval [CI]: 2.6, 4.2) and 2.8 (95% CI: 1.8, 4.4) for women with a false-positive screening without and with needle biopsy, respectively. Women with a previous negative screening had a significantly lower proportion of tumors that were 10 mm or less (14.3% [150 of 1049] vs 50.0% [seven of 14], respectively; P < .01) and grade I tumors (13.2% [147 of 1114] vs 42.9% [six of 14]; P < .01), but a higher proportion of cases with lymph nodes positive for cancer (40.9% [442 of 1080] vs 13.3% [two of 15], respectively; P = .03) compared with women with a previous false-positive screening with benign biopsy. A retrospective review of the screening mammographic examinations identified 42.9% (39 of 91) of the false-positive cases to be the same lesion as the IBC. Conclusion By using a negative screening as the reference, a false-positive screening examination increased the risk of an IBC three-fold. The tumor characteristics of IBC after a negative screening were less favorable compared with those detected after a previous false-positive screening. © RSNA, 2017 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Hofvind S, Sagstad S, Sebuødegård S, et al. Interval Breast Cancer Rates and Histopathologic Tumor Characteristics after False-Positive Findings at Mammography in a Population-based Screening Program. Radiology. 2017. PMID: 29239711. doi:10.1148/radiol.2017162159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。